Clinical outcomes with betahistine in vestibular disorders
|
|
- Benedict Preston
- 5 years ago
- Views:
Transcription
1 Clinical outcomes with betahistine in vestibular disorders Michael Strupp MD, FRCP, FANA, FEAN Department of Neurology, German Center for Vertigo and Balance Disorders University of Munich
2 Role of betahistine in the treatment of vertigo - 4,294 patients with vertigo (REVERT registry) international centers: 13 countries over 28 months 1 Diagnosis Treatment 0% 10% 20% 30% 40% 50% 60% 70% 20,5% 37,2% 15,4% 26,9% Betahistine Piracetam Ginkgo biloba Other vertigo therapy Diuretics Benzodiazepines Antihistamines Meniere's disease BPPV Other vertigo of peripheral vestibular origin Peripheral vestibular vertigo of unknown origin Neuroleptics Calcium antagonists Homeopathics 1 Agus S, et al. Front Neurol 2013;4:48
3 Betahistine for the treatment of - Acute vertigo - Menière s disease - animal and clinical studies - limitations and perspectives
4 Animal models of Unilateral Labyrinthectomy (UL) Surgical labyrinthectomy Chemical labyrinthectomy irreversible Arsenilat/Bupivacain irreversible Bupivacain reversible repetitive Zwergal et al. Klinik und Poliklinik für Nuklearmedizin - LMU
5 Behavioural compensation after unilateral labyrinthectomy Postural asymmetry Klinik und Poliklinik für Nuklearmedizin - LMU
6 Animal model of unilateral labyrinthectomy
7 Effects of betahistine in unilateral labyrinthectomy on BALANCE BETAHISTINE iv. versus SHAM treatment i.v. injection (1mg/kg BID day 1-3) Behavioral scoring postural asymmetry Mean of score Range 0-10
8 Effect of betahistine in unilateral labyrinthectomy on GAIT: day 8 Control Betahistine
9 Effects of betahistine in unilateral labyrinthectomy on GAIT VELOCITY OPEN FIELD osmotic pump Velocity 5x Betahistine NaCl
10 Micro-FDG PET of the rat brain - challenges anatomy Klinik und Poliklinik für Nuklearmedizin - LMU
11 Micro-FDG-PET data processing 3D statistical parametric maps group maps 3 individual µpet data 2 1 FDR p<0.05 Zwergal et al Klinik und Poliklinik für Nuklearmedizin - LMU
12 Betahistine in unilateral labyrinthectomy: Double effect: acute and on central compensation Zwergal et al.
13 Menière s disease new diagnostic criteria Consensus document of the Bárány Society, the Japan Society for Equilibrium Research, the European Academy of Otology and Neurotology (EAONO), AAO-HNS and the Korean Neurotology Society J.A. Lopez-Escamez, J. Carey, W.-H. Chung, J.A. Goebel, J. Magnan, M. Mandala, D.E. Newman-Toker, M. Strupp, M. Suzuki and A. Bisdorff 1861 Definite Menière s disease: two or more attacks of vertigo, each lasting 20 min to 12 h audiometrically documented hearing loss in at least one examination (< 2000 Hz, > 30dB) and related to the attacks fluctuating tinnitus or aural fullness in the affected ear not better accounted for by another vestibular diagnosis J Vest R 2015 OPEN ACCESS
14 Efficacy and safety of betahistine treatment in patients with Menière s disease: primary results of long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial) Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M (2016) BMJ 221 pts, 14 centers: incidence of attacks related to Menière s disease did NOT differ between the three treatment groups (placebo, 16 mg tid, 48 tid mg (p=0.759)).
15
16 Observational study on 11 patients with MD who did not sufficiently respond to 144 mg betahistine per day - dosage: mg per day - mean treatment period: 4.1 ± 1.4 years - side effects: 4 mild gastrointestinal 1 fatigue 1 altered taste none had to stop the treatment F. Lezius, C. Adrion, U. Mansmann, K. Jahn, M. Strupp (2011) Eur Arch Otorhinolarngol
17 Nmber of patients > 6 months no attacks Clinical practice: pharmacotherapy of Menière s disease: > 144 mg/d betahistine > 6 months free of attacks Daily dosage of betahistine (mg) Strupp et al. Frontiers Neuro-otol (2017)
18 The effect of betahistine on cochlear microcirculation in guinea pigs in vivo F. Ihler, M. Bertlich, M. Canis, M. Strupp
19 Animal model Canis et. al Eur Arch Otorhinolaryngol
20 Previous studies Dziadziola et. al Otolaryngol Head Neck Surg mg/kg b. w. Laurikainen et. al Acta Otolaryngol ca mg/kg b. w.? Lamm & Arnold 2000 Hear Res 0.15 mg/kg b. w. Meyer et. al Laryngorhinootologie 0.11 mg/kg b. w. Strupp et. al Acta Otolaryngol und BEMED 2x 24 mg versus 3x 48 mg calculated corresponding dosage for equivalent peak concentration when administered orally mg/kg KG Current study treatment group 1: 1.0 mg/kg b. w. treatment group 2: 0.1 mg/kg b. w. treatment group 3: 0.01 mg/kg b. w treatment group 4: mg/kg b. w. control group: Placebo (NaCl 0.9%)
21 Results Dose-response curve: Cochlear cochlear blood flowblood flow (CBF) peak fold change from basal value 1,5 1,4 1,3 1,2 1,1 48 mg 24 mg 16 mg 160 mg * * Calculated corresponding single dosages when administered orally (Chen et al. 2003) 1,0 0,0001 0,001 0,01 0, dosage [mg/kg b. w.] (treatment group) mean +/- SEM; *: p < 0.05 vs. placebo (ANOVA on ranks/dunn s) F. Ihler, M. Bertlich, M. Canis, M. Strupp (2012) PLoS ONE
22 Betahistine metabolites aminoethylpyridine and hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo Mattis Bertlich, Fritz Ihler, Kariem Sharaf, Bernhard Weiss, Michael Strupp, Martin Canis Int J Audiol (2014)
23 Mode of action of betahistine: increase of cochlear blood flow via its action as an inverse agonist of the H3 heteroreceptors (blocking of the H3 receptor with proxyfan or thioperamide caused a suppression of betahistine effects on cochlear blood flow) M. Bertlich, F. Ihler, S. Freytag, B.G. Weiss, M. Strupp, M. Canis. Int J Audiol (2015)
24 Expression of histamine receptors in the human endolymphatic sac: the molecular rationale for betahistine use in Menières disease M. Nue Møller et al (2016) Eur Arch Otorhinolaryngol Immuno-histochemical demonstration of histamine H1 receptor (HRH1) expression in the human endolymphatic sac: epithelial lining with an intense labeling in most cells both apically and basally (* endolymphatic sac). Histamine H3 receptor (HRH3) expression in the subepithelial capillary network of the human endolymphatic sac.
25 Mode of action of betahistine: Dilatation of precapillary arterioles Bertlich et al. Life Sci (2017)
26 Treatment of Menière s disease Betahistine-dihydrochloride: BEMED trial: (221 pts, 16 mg tid, 48 mg tid vs plac.) negative, therefore: 96 mg tid 12 months ( much and long-term ) up to 1920! mg/d, i.e. 80 tablets per day (Strupp et al. 2017) observational study: 11 pts 288 mg to 480 mg per day rarely: intratympanic gentamicin not effective: - endolymphatic sac operation (Pullens et al. (2013) Cochrane Rev) - salt-free diet (no state of the art clinical trial) - diuretics (Thirlwall AS, Kundu S (2006) Cochrane Rev) - Meniett device (Russo et. (2017) Laryngoscope) - intratympanic dexamethasone (Otonomy press release, )
27 Basic problem: betahistine pharmacokinetics Orally-administered betahistine: rapidly and almost completely metabolized into 2-pyridylacetic acid (2-PAA; no known pharmacological activity) The two other metabolites: pharmacologically active, but short half-life time Absolute bioavailability of oral betahistine: ~1% Plasma levels of betahistine are very low: high inter-subject variability Challenge to increase plasma exposure
28 Relative to C max oral administration Intranasal delivery: superior systemic exposure C max Betahistine in Plasma Oral Întranasal Intranasal Reference = 3x maximum approved oral dose Single-dose phase 1 study with intranasal delivery in healthy volunteers: - dose-dependent betahistine concentration in blood plasma (T max ~10 min post-dose) - significantly higher plasma concentrations C max than with oral dosing Auris Medical
29 Betahistine for the treatment of acute vertigo and Menière s disease: It is effective all a question of the dosage or application form due to the 99% first-pass effect Next step: randomized controlled trials
AM-125 : Intranasal Betahistine
AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationClinical-Stage Project Development Update
Clinical-Stage Project Development Update June 16, 2017 NASDAQ: EARS Agenda Welcome and Introduction Cindy McGee Keyzilen (AM-101) and AM-111 Project Updates Thomas Meyer Treating Patients with Vestibular
More informationPage: 1 of 6. Transtympanic Micropressure Applications as a Treatment of Meniere's Disease
Page: 1 of 6 Last Review Status/Date: December 2013 as a Treatment of Meniere's Disease Description Transtympanic micropressure treatment for Meniere s disease involves use of a hand-held air pressure
More informationTranstympanic Micropressure Applications as a Treatment of Meniere s Disease
Transtympanic Micropressure Applications as a Treatment of Meniere s Disease Policy Number: 1.01.23 Last Review: 8/2014 Origination: 2/2006 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas
More informationTranstympanic Micropressure Applications as a Treatment of Meniere s Disease
Transtympanic Micropressure Applications as a Treatment of Meniere s Disease Policy Number: 1.01.23 Last Review: 8/2017 Origination: 2/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationRESEARCH. open access
open access Efficacy and safety of betahistine treatment in patients with Meniere s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial
More informationHistaminergic H 3 -Heteroreceptors as a Potential Mediator of Betahistine- Induced Increase in Cochlear Blood Flow
Audiology Neurotology Original Paper Received: February 20, 2014 Accepted: September 10, 2014 Published online: June 27, 2015 Histaminergic H 3 -Heteroreceptors as a Potential Mediator of Betahistine-
More informationCorporate Medical Policy
Corporate Medical Policy Transtympanic Micropressure Applications as a Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: transtympanic_micropressure_applications_as_a_treatment_of_menieres_disease
More informationEffect of Intratympanic Dexamethasone on Controlling Tinnitus and Hearing loss in Meniere s Disease
Original Article Iranian Journal of Otorhinolaryngology, Vol.26(3), Serial No.76, Jul 2014 Effect of Intratympanic Dexamethasone on Controlling Tinnitus and Hearing loss in Meniere s Disease Abstract Faramarz
More informationHearing Function After Intratympanic Application of Gadolinium- Based Contrast Agent: A Long-term Evaluation
The Laryngoscope VC 2015 The American Laryngological, Rhinological and Otological Society, Inc. Hearing Function After Intratympanic Application of Gadolinium- Based Contrast Agent: A Long-term Evaluation
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Patel M, Agarwal K, Arshad Q, et al. Intratympanic
More informationDelayed Endolymphatic Hydrops: Episodic Vertigo of Delayed Onset after Profound Inner Ear Hearing Loss
Delayed Endolymphatic Hydrops: Episodic Vertigo of Delayed Onset after Profound Inner Ear Hearing Loss Tamio Kamei 1, MD, PhD and Kenji Watanabe 2, MD 1 Professor emeritus at Gunma University, Japan 2
More informationResponse Over Time of Vertigo Spells to Intratympanic Dexamethasone Treatment in Meniere s Disease Patients
J Int Adv Otol 2016; 12(1): 95-100 DOI: 10.5152/iao.2016.2177 Original Article Response Over Time of Vertigo Spells to Intratympanic Dexamethasone Treatment in Meniere s Disease Patients Nabil Atrache
More informationDrug delivery to the inner ear
Intratympanic Drug Delivery Society of Otorhinolaryngology and Head-Neck Nurses Advantages of intratympanic delivery Higher concentration of drug at site of action Avoid systemic effects May be able to
More informationO-VERT (BETAHISTINE hydrochloride) 8 mg & 16 mg TABLET
O-VERT (BETAHISTINE hydrochloride) 8 mg & 16 mg TABLET ANTI-VERTIGO Page 1 of 5 BETAHISTINE HYDROCHLORIDE STRUCTURAL FORMULA MOLECULAR WEIGHT 209.116196 MOLECULAR FORMULA C 8 H 14 Cl 2 N 2 CHEMICAL NAME
More informationADVERSE EFFECTS OF PROCHLORPERAZINE
ADVERSE EFFECTS OF PROCHLORPERAZINE Extrapyramidal effects like acute dystonic reactions, oculogyric crises, pseudo parkinsonism and akathisia are the major drawbacks - more common in children and adolescents.
More informationHistamine s Role in Vestibular Function and Recovery
Histamine s Role in Vestibular Function and Recovery Brahim Tighilet Laboratoire de Neurosciences Intégratives et Adaptatives UMR 7260-Fed 3C Physiologie et thérapie des désordres vestibulaires Aix-Marseille
More informationMeniere s disease and Sudden Sensorineural Hearing Loss
Meniere s disease and Sudden Sensorineural Hearing Loss Tsutomu Nakashima 1,2 1 Ichinomiya Medical Treatment & Habilitation Center, Ichinomiya, Japan 2 Department of Otorhinolaryngology, Nagoya University,
More informationVery few dizzy conditions have a surgical treatment SURGICAL MANAGEMENT OF THE DIZZY PATIENT. Surgical Treatments for. Shunts and Sac Surgery
SURGICAL MANAGEMENT OF THE DIZZY PATIENT Very few dizzy conditions have a surgical treatment Timothy C. Hain, M.D. Meniere s Disease Perilymphatic Fistula (PLF) Superior Canal Dehiscence (SSD) Benign Paroxysmal
More informationMÉNIÈRE S DISEASE (MD)
Progression of Symptoms of Dizziness in Ménière s Disease Mari Havia, MD; Erna Kentala, MD, PhD ORIGINAL ARTICLE Objective: To evaluate the progression of symptoms of dizziness in Ménière s disease (MD)
More informationThe vascular mechanism of action of betahistine in the inner ear of the guinea pig
Eur Arch Otorhinolaryngol (1998) 255 : 119 123 Springer-Verlag 1998 OTOLOGY E. Laurikainen J. M. Miller A. L. Nuttall W. S. Quirk The vascular mechanism of action of betahistine in the inner ear of the
More informationUNILATERAL MENIERE S DISEASE; INTRA TYMPANIC INJECTION OF LOW DOSE GENTAMICIN IN THE TREATMENT
The Professional Medical Journal DOI: 10.17957/TPMJ/16.3129 ORIGINAL PROF-3129 UNILATERAL MENIERE S DISEASE; INTRA TYMPANIC INJECTION OF LOW DOSE GENTAMICIN IN THE TREATMENT 1. Professor and Consultant
More informationIntratympanic Injections of a Pharmacologic Agent for the Treatment of Meniere s Disease or Sudden Hearing Loss. Original Policy Date
MP 2.01.47 Intratympanic Injections of a Pharmacologic Agent for the Treatment of Meniere s Disease or Sudden Hearing Loss Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last
More informationLabyrinth Anesthesia A Forgotten but Practical Treatment Option in Ménière s Disease
Original Paper ORL 2003;65:84 90 DOI: 10.1159/000070771 Received: February 20, 2003 Accepted: March 6, 2003 Labyrinth Anesthesia A Forgotten but Practical Treatment Option in Ménière s Disease Oliver Adunka
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Proposed Version 1/9 1. NAME OF THE MEDICINAL PRODUCT Betaserc 24 mg orodispersible tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betaserc 24 mg orodispersible
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationTreatment of Menière s Disease
Curr Treat Options Neurol (2015) 17:14 DOI 10.1007/s11940-015-0341-x Neurologic Ophthalmology and Otology (RK Shin and DR Gold, Section Editors) Treatment of Menière s Disease Jeffrey D. Sharon, MD * Carolina
More informationCochlear Implant Impedance Fluctuation in Ménière s Disease: A Case Study
Otology & Neurotology xx:xx xx ß 2016, Otology & Neurotology, Inc. Cochlear Implant Impedance Fluctuation in Ménière s Disease: A Case Study Celene McNeill and Kate Eykamp Healthy Hearing and Balance Care,
More informationMénière`s disease is a frequent vestibular disease that
Rev Bras Otorrinolaringol 2007;73(3):346-50. ORIGINAL ARTICLE The outcome of patients with ménière s disease Adriana Gonzaga Chaves 1, Letícia Boari 2, Mário Sérgio Lei Munhoz 3 Keywords: ménière`s disease,
More informationCITY & HACKNEY PATHFINDER CLINICAL COMMISSIONING GROUP. Vertigo. (1) Vertigo. (4) Provisional Diagnosis. (5) Investigations. lasting days or weeks
Authors: Dr Lucy O'Rouke and Mr N Eynon-Lewis Review date: January 2017 Vertigo (1) Vertigo (2) History (3) Examination (4) Provisional Diagnosis (5) Investigations (6) Medical Cause (7) Psychiatric Cause
More informationEvaluation of the Adult Dizzy Patient Elizabeth Kelly, MD Boys Town National Research Hospital ENT Institute Neurotology/Otology September 27, 2018
Evaluation of the Adult Dizzy Patient Elizabeth Kelly, MD Boys Town National Research Hospital ENT Institute Neurotology/Otology September 27, 2018 No disclosures Objectives Describe different presentations
More informationHearing Outcome of Low-tone Compared to High-tone Sudden Sensorineural Hearing Loss
THIEME Original Research Hearing Outcome of Low-tone Compared to High-tone Sudden Sensorineural Hearing Loss George Psillas 1 Aikaterini Rizou 1 Dimitrios Rachovitsas 1 Gabriel Tsiropoulos 1 Jiannis Constantinidis
More information15 Marzo 2014 Aspetti radiologici dei disordini vestibolari: approccio multidisciplinare
15 Marzo 2014 Aspetti radiologici dei disordini vestibolari: approccio multidisciplinare MR Imaging of inner ear endo-perilymphatic spaces at 3T after intratympanic contrast agent administration in Definite
More informationIntratympanic Therapies for Menière s Disease
Curr Otorhinolaryngol Rep (2014) 2:137 143 DOI 10.1007/s40136-014-0055-8 MENIERE S DISEASE (L LUSTIG, SECTION EDITOR) Intratympanic Therapies for Menière s Disease Matthew W. Miller Yuri Agrawal Published
More informationClinical Characteristics of Labyrinthine Concussion
online ML Comm ORIGINAL ARTICLE Korean J Audiol 2013;17:13-17 pissn 2092-9862 / eissn 2093-3797 http://dx.doi.org/10.7874/kja.2013.17.1.13 Clinical Characteristics of Labyrinthine Concussion Mi Suk Choi,
More informationETHICAL & RATIONAL MANAGEMENT OF VERTIGO
...Pharma Company ETHICAL & RATIONAL MANAGEMENT OF VERTIGO -drugs & other modalities Drugs Maneuvers Physical Therapy Non specific Symptomatic therapy Specific therapy to treat the underlying disorder
More informationDiagnostic criteria for vestibular neuritis
Equilibrium Res Vol. (4) Bárány Society Diagnostic criteria for vestibular neuritis Toshihisa Murofushi Department of Otolaryngology Teikyo University School of Medicine Mizonokuchi Hospital The authors
More informationHow to take the patient history
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Hands-on Course 3 Bedside examination of the vestibular and ocular motor system - Level 2 How to take the
More informationWhat could be reffered to as dizziness by the patient?
What could be reffered to as dizziness by the patient? Rotational vertigo Sense of instability Ataxia of gait Disturbance of vision Loss of contact with surroundings Nausea Loss of memory Loss of confidence
More informationNormal membranous labyrinth. Dilated membranous labyrinth in Meniere's disease (Hydrops)
Meniere s Disease Normal membranous labyrinth Dilated membranous labyrinth in Meniere's disease (Hydrops) Normal membranous labyrinth Dilated membranous labyrinth in Meniere's disease (Hydrops) DEFINITION
More informationOcular Vestibular Evoked Myogenic Potentials to Air Conducted Tone Bursts in Patients with Unilateral Definite Ménière s Disease
Int. Adv. Otol. 2013; 9:(2) 180-185 ORIGINAL AERICLE Ocular Vestibular Evoked Myogenic Potentials to Air Conducted Tone Bursts in Patients with Unilateral Definite Ménière s Disease Mohamed M Abdeltawwab
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationFirst a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.
Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,
More informationThe concept of Menière s disease
treatment of Dr Louis M Hofmeyr MBChB (Pret), MMed ENT (Pret) Department of ENT, 1 Military Hospital and Institute for Aviation Medicine Introduction is a fascinating condition. I have had a particular
More informationMRI Inner Ear Imaging and Tone Burst Electrocochleography in the Diagnosis of
Otology & Neurotology 36:1109Y1114 Ó 2015, Otology & Neurotology, Inc. MRI Inner Ear Imaging and Tone Burst Electrocochleography in the Diagnosis of Ménière s Disease * Jeremy Hornibrook, *Edward Flook,
More informationVertigo. Tunde Magyar MD, PhD
Vertigo Tunde Magyar MD, PhD What could be reffered to as dizziness by the patient? Rotational vertigo Sense of instability Ataxia of gait Disturbance of vision Loss of contact with surroundings Nausea
More informationAUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 1 NAME OF THE MEDICINE Betahistine dihydrochloride. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
More informationIntratympanic steroid injection as a salvage treatment for sudden sensorineural hearing loss
The Journal of Laryngology & Otology, 1 of 6. JLO (1984) Limited, 2014 doi:10.1017/s0022215114002710 MAIN ARTICLE Intratympanic steroid injection as a salvage treatment for sudden sensorineural hearing
More informationClinical Characteristics and Short-term Outcomes of Acute Low Frequency Sensorineural Hearing Loss With Vertigo
Original Article Clinical and Experimental Otorhinolaryngology Vol. 11, No. 2: 96-101, June 2018 https://doi.org/10.21053/ceo.2017.00948 pissn 1976-8710 eissn 2005-0720 Clinical Characteristics and Short-term
More informationSudden Sensorineural Hearing Loss; Prognostic Factors
Original Article Iranian Journal of Otorhinolaryngology, Vol.27(5), Serial No.82, Sep 2015 Abstract Sudden Sensorineural Hearing Loss; Prognostic Factors Dass Arjun 1, * Goel Neha 1, Singhal Surinder K
More informationG. Doobe, 1 A. Ernst, 1 R. Ramalingam, 2 P. Mittmann, 1 and I. Todt Introduction. 2. Materials and Methods
BioMed Research International Volume 2015, Article ID 457318, 4 pages http://dx.doi.org/10.1155/2015/457318 Research Article Simultaneous Labyrinthectomy and Cochlear Implantation for Patients with Single-Sided
More informationMonitoring of Caloric Response and Outcome in Patients With Benign Paroxysmal Positional Vertigo
Otology & Neurotology 28:798Y800 Ó 2007, Otology & Neurotology, Inc. Monitoring of Caloric Response and Outcome in Patients With Benign Paroxysmal Positional Vertigo *Maria I. Molina, *Jose A. López-Escámez,
More informationEndolymphatic Duct Blockage for Refractory Ménière s Disease: Assessment of Endolymphatic Sac Biopsy on Short-Term Surgical Outcomes
J Int Adv Otol 2016; 12(3): 310-5 DOI: 10.5152/iao.2016.3069 Original Article Endolymphatic Duct Blockage for Refractory Ménière s Disease: Assessment of Endolymphatic Sac Biopsy on Short-Term Surgical
More informationBecause dizziness is an imprecise term, a major role of the clinician is to sort patients out into categories
Dizziness and Imbalance Timothy C. Hain, MD Clinical Professor of Neurology, Otolaryngology, Physical Therapy Chicago Dizziness and Hearing 645 N. Michigan, Suite 410 312-274-0197 Lecture Goals 1. What
More informationIntratympanic Gentamicin Therapy for Vertigo in Nonserviceable Ears
Intratympanic Gentamicin Therapy for Vertigo in Nonserviceable Ears Paul W. Bauer, MD, C. Bruce MacDonald, MD, and L. Clarke Cox, PhD Purpose: Intratympanic ototoxic agents have become a widely accepted
More informationPositive pressure therapy for Ménière s disease or syndrome(review)
Cochrane Database of Systematic Reviews Positive pressure therapy for Ménière s disease or syndrome (Review) vansonsbeeks,pullensb,vanbenthempp vansonsbeeks,pullensb,vanbenthempp. Positive pressure therapy
More informationRelieve your vertigo symptoms with a simple and effective treatment for Ménière s disease
Relieve your vertigo symptoms with a simple and effective treatment for Ménière s disease Ménière s Disease Ménière s disease is a complex inner ear condition that can be unpredictable and disabling. Usually
More informationreview of literature
ISSN: 2250-0359 Volume 5 Issue 2 2015 Bilateral Meniere s disease in the young, Dilemma s in medical management: A critical review of literature Sahoo Kumar Anjan, Preetam Chappity, Kumar Rajeev A.I.I.M.S,
More informationHearing fluctuation is not a predictor of vertigo attacks in Meniere s syndrome
52 Celene Mc Neill MA 1,2 William Gibson MD 3,4 Alan Taylor PhD 2 Hearing fluctuation is not a predictor of vertigo attacks in Meniere s syndrome Abstract 1 Healthy Hearing & Balnace Care, Sydney, Australia.
More informationMénière s Society. Do you suffer from dizziness and imbalance as a result of a vestibular disorder?
Survey 2015 Ménière s Society The Rookery, Surrey Hills Business Park, Wotton, Surrey RH5 6QT. UK. +44 (0)1306 876883 info@menieres.org.uk www.menieres.org.uk Registered Charity No. 297246 Do you suffer
More informationALESSANDRA RUSSO MD GRUPPO OTOLOGICO
Gruppo Otologico Simultaneous Labyrinthectomy with Cochlear Implantation Cenacolo di Audiovestibologia, Chieti, 24-25/06/2016 ALESSANDRA RUSSO MD GRUPPO OTOLOGICO MENIERE DISEASE Therapeutic Steps 1 step
More informationClinical Indicators Useful in Predicting Response to the Medical Management of Meniere s Disease
The Laryngoscope Lippincott Williams & Wilkins, Inc., Philadelphia 2000 The American Laryngological, Rhinological and Otological Society, Inc. Clinical Indicators Useful in Predicting Response to the Medical
More informationPeripheral vestibular disorders
REVIEW C URRENT OPINION Peripheral vestibular disorders Michael Strupp a,b and Thomas Brandt b,c Purpose of review First, to update the diagnosis, pathophysiology, and treatment of the most frequent peripheral
More informationEndolymphatic hydrops in patients with vestibular migraine and auditory symptoms
DOI 10.1007/s00405-013-2751-2 OTOLOGY Endolymphatic hydrops in patients with vestibular migraine and auditory symptoms Robert Gürkov Claudia Kantner Michael Strupp W. Flatz Eike Krause Birgit Ertl-Wagner
More informationSudden sensorineural hearing loss (SSNHL) is defined
Transtympanic steroids for treatment of sudden hearing loss GERARD J. GIANOLI, MD, FACS, and JOHN C. LI, MD, FACS, Baton Rouge, Louisiana, and Jupiter, Florida OBJECTIVES: To determine whether transtympanic
More informationTreatment modalities of vertigo
Treatment modalities of vertigo Beata Bencsik MD, PhD Semmelweis University, Department of Otorhinolaryngology and Head and Neck Surgery Common statements made by vertigo patients Doctor, you are my last
More informationPRODUCT MONOGRAPH. Betahistine Dihydrochloride Tablets, House Standard. 16 mg and 24 mg. Anti-vertigo Agent
PRODUCT MONOGRAPH Pr pms-betahistine Betahistine Dihydrochloride Tablets, House Standard 16 mg and 24 mg Anti-vertigo Agent PHARMASCIENCE INC. 6111 Royalmount Ave. suite 100 Montreal, Quebec H4P 2T4 Date
More informationANTERIOR CANAL BPPV and its controversies. Marco Mandalà
ANTERIOR CANAL BPPV and its controversies. Marco Mandalà Otology and Skull Base Surgery Department University of Siena, Italy AC-BPPV HISTORY (vs PC) AC-BPPV PC-BPPV 1921, Barany first description 1952,
More informationPRODUCT MONOGRAPH. Betahistine Dihydrochloride Tablets. 8 mg, 16 mg and 24 mg. Anti-vertigo Agent
PRODUCT MONOGRAPH Pr TEVA-BETAHISTINE Betahistine Dihydrochloride Tablets 8 mg, 16 mg and 24 mg Anti-vertigo Agent Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 www.tevacanada.com
More informationDENOMINATOR: All patients aged birth and older presenting with acute or chronic dizziness
Quality ID #261: Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationA Case of Drastic Improvement in a 43 Year Old Male with Severe Refractory Incapacitating Vertigo
British Journal of Medicine & Medical Research 4(35): 5635-5641, 2014 SCIENCEDOMAIN international www.sciencedomain.org A Case of Drastic Improvement in a 43 Year Old Male with Severe Refractory Incapacitating
More informationHyperbaric Oxygen for Idiopathic Sudden Sensorineural Hearing Loss
Hyperbaric Oxygen for Idiopathic Sudden Sensorineural Hearing Loss Leonardo Profenna, MD, MPH Medical Director of Wound Care and Hyperbaric Medicine Connally Memorial Medical Center Introduction - ISSHL
More informationAuris Medical Holding
Auris Medical Holding Treating vertigo Initiation of coverage Pharma & biotech Auris Medical is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner
More informationComplete recovery following hyperbaric oxygen therapy in idiopathic sudden sensorineural hearing loss: a report of two cases
Complete recovery following hyperbaric oxygen therapy in idiopathic sudden sensorineural hearing loss: a report of two cases Swati Agrawal 1, Nishi Sharma 2 1 Senior Resident, 2 Professor, Department of
More informationWestminsterResearch
WestminsterResearch http://www.westminster.ac.uk/westminsterresearch Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative
More informationWhat is Meniere's disease? What causes Meniere's disease?
NIH Publication No 95-3403 November 1994 What is Meniere's disease? Meniere's disease is an abnormality of the inner ear causing a host of symptoms, including vertigo or severe dizziness, tinnitus or a
More informationPRODUCT MONOGRAPH. SERC betahistine dihydrochloride tablets (16 mg and 24 mg)
PRODUCT MONOGRAPH Pr SERC betahistine dihydrochloride tablets (16 mg and 24 mg) Anti-vertigo Agent Registered Trade-mark Abbott Products Operations AG, Licensed use by BGP Pharma ULC, Saint-Laurent, Quebec,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationEndolymphatic Sac Surgery for Ménière s Disease Current Opinion and Literature Review
THIEME Systematic Review The Surgical Management of Vestibular Disorders 179 Endolymphatic Sac Surgery for Ménière s Disease Current Opinion and Literature Review Maria de Lourdes Flores García 1 Carolina
More informationIntratympanic Steroid Treatment as a Primary Therapy in Idiopathic Sudden Sensorineural Hearing Loss
Int. Adv. Otol. 2009; 5:(3) 334-339 ORIGINAL ARTICLE Intratympanic Steroid Treatment as a Primary Therapy in Idiopathic Sudden Sensorineural Hearing Loss Ljiljana Cvorovic, Mile Strbac, Milan B. Jovanovic,
More informationTenotomy of the middle ear muscles causes a dramatic reduction in vertigo attacks and improves audiological function in definite Meniere s disease
Acta Oto-Laryngologica, ; Early Online, 7 ORIGINAL ARTICLE Tenotomy of the middle ear muscles causes a dramatic reduction in vertigo attacks and improves audiological function in definite Meniere s disease
More informationStudy on Hearing Status of Elderly Patients attending a Specialized ENT Hospital (SAHIC)
Bangladesh J Otorhinolaryngol 2015; 21(2): 80-84 Original Article Study on Hearing Status of Elderly Patients attending a Specialized ENT Hospital (SAHIC) Mohammad Wakilur Rahman 1, Ali Imam Ahasan 2,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationVestibular Schwannoma and Ipsilateral Endolymphatic Hydrops: An Unusual Association
CASE REPORT DOI: 10.5935/0946-5448.20170024 International Tinnitus Journal. 2017;21(2):128-132. Vestibular Schwannoma and Ipsilateral Endolymphatic Hydrops: An Unusual Association Massimo Ralli 1 Antonio
More informationSafety of Repeated Intratympanic AM-101 in Acute Inner Ear Tinnitus. AAO-HNSF San Diego 2016
Safety of Repeated Intratympanic AM-101 in Acute Inner Ear Tinnitus AAO-HNSF San Diego 2016 Hinrich Staecker, Department Otolaryngology Head and Neck Surgery, University of Kansas Pavel Chrbolka, MediORL
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More informationEffects of Hyperbaric Therapy on Function and Morphology of Guinea Pig Cochlea with Endolymphatic Hydrops
Otology & Neurotology 25:553 558 2004, Otology & Neurotology, Inc. Effects of Hyperbaric Therapy on Function and Morphology of Guinea Pig Cochlea with Endolymphatic Hydrops Fang-Lu Chi, Qin Liang, and
More informationClinically applicable objective diagnosis of Ménière's disease by MR: How "to do" it
Clinically applicable objective diagnosis of Ménière's disease by MR: How "to do" it Poster No.: C-0488 Congress: ECR 2013 Type: Authors: Keywords: DOI: Educational Exhibit S. Naganawa, M. Yamazaki, H.
More informationMigraine Features in Patients With Meniere s Disease
The Laryngoscope VC 2015 The American Laryngological, Rhinological and Otological Society, Inc. Migraine Features in Patients With Meniere s Disease Yaser Ghavami, MD; Hossein Mahboubi, MD, MPH; Amy Y.
More informationEFFICACY AND SAFETY OF INTRATYMPANIC STEROID TREATMENT FOR IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS
Original research article International Journal of Medical Science and Education pissn- 2348 4438 eissn-2349-3208 EFFICACY AND SAFETY OF INTRATYMPANIC STEROID TREATMENT FOR IDIOPATHIC SUDDEN SENSORINEURAL
More informationPersistent Postural-Perceptual Dizziness (PPPD) and Other Chronic Vestibular and Balance Problems
Minnesota Physical Therapy Association Annual Conference Persistent Postural-Perceptual Dizziness (PPPD) and Other Chronic Vestibular and Balance Problems Jeffrey P. Staab, MD, MS Professor of Psychiatry
More informationORIGINAL ARTICLE. Comparison of hearing recovery criteria in sudden sensorineural hearing loss
Braz J Otorhinolaryngol. 2012;78(3):42-8. ORIGINAL ARTICLE BJORL Comparison of hearing recovery criteria in sudden sensorineural hearing loss Daniel Paganini Inoue 1, Eduardo Amaro Bogaz 2, Flávia Barros
More informationIntratympanic Steroid Therapy in Moderate Sudden Hearing Loss: A Randomized, Triple-Blind, Placebo-Controlled Trial
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Intratympanic Steroid Therapy in Moderate Sudden Hearing Loss: A Randomized, Triple-Blind, Placebo-Controlled
More informationManagement of Ear, Hearing and Balance Disorders: Fact, Fiction, and Future
Management of Ear, Hearing and Balance Disorders: Fact, Fiction, and Future George W. Hicks, M,D. 7440 N. Shadeland Avenue, Suite 150 Indianapolis, IN 46250 904 N. Samuel Moore Parkway Mooresville, IN
More informationMenièré s Disease. Overview. Clinical Presentation. Pathology. Intratympanic therapy. Mitchell Ramsey, MD Tripler Army Medical Center
Menièré s Disease Mitchell Ramsey, MD Tripler Army Medical Center Overview Clinical Presentation Pathology Intratympanic therapy Clinical Manifestations Classical type (1861) Vertigo, hearing loss, tinnitus,
More informationThe Dizziness Handicap Inventory and Its Relationship with Vestibular Diseases
Int. Adv. Otol. 2012; 8:(1) 69-77 ORIGINAL ARTICLE The Dizziness Handicap Inventory and Its Relationship with Vestibular Diseases Mi Joo Kim, Kyu-Sung Kim, Yeon Hee Joo, Soo Young Park, Gyu Cheol Han Department
More informationAutonomic Dysfunction in Patients with Vertigo
Review Article Autonomic Dysfunction in JMAJ 49(4): 153 157, 26 Noriaki Takeda 1 Abstract Autonomic function and vertebral blood flow were measured in patients with vertigo. Based on our findings obtained
More informationVestibular Migraine Panel Session. Panelists. Learner Objectives 7/31/2017. Steven Harvey MD. Fallon Schloemer MD.
Vestibular Migraine Panel Session David R. Friedland MD, PhD Professor and Vice-Chair Chief, Division of Otology and Neuro- Otologic Skull Base Surgery Panelists Steven Harvey MD Neuro-otologist Fallon
More information